Charlotte Jovenin
About Charlotte Jovenin
Charlotte Jovenin is a Déléguée Hospitalière Immuno-Oncologie at Bristol-Myers Squibb in Paris, France, with over 19 years of experience in the pharmaceutical industry.
Current Role at Bristol-Myers Squibb
Charlotte Jovenin is currently serving as a Déléguée Hospitalière Immuno-Oncologie at Bristol-Myers Squibb. Based in Paris, France, she oversees a substantial territory covering Lille, Amiens, Rouen, and Caen in the Région de Lille area. Her role involves extensive engagement with healthcare professionals, ensuring the effective communication and implementation of immuno-oncological therapies.
Previous Experience in Neurosciences
Prior to her current position, Charlotte worked as a Déléguée Hospitalière Neurosciences at Bristol-Myers Squibb from 2004 to 2011. During her seven-year tenure in this role, she was responsible for liaising with medical institutions in the Région de Lille, France, to promote neurological therapies.
Educational Background
Charlotte Jovenin studied at Université Paris Descartes, where she specialized in Thérapeutiques Immunologiques. She achieved a Diplôme Universitaire (DU) in this field, which has significantly contributed to her expertise in immuno-oncology. This educational background equipped her with the foundational knowledge essential for her roles in the pharmaceutical industry.
Experience in Immuno-Oncology
Charlotte has been working in the field of immuno-oncology for over a decade. Her transition from neurosciences to immuno-oncology occurred in 2011, marking a significant shift in her career focus. This experience has provided her with in-depth knowledge and proficiency in handling immuno-oncological products and therapies, benefiting her interactions with healthcare professionals.
Years of Service at Bristol-Myers Squibb
With over 19 years of experience at Bristol-Myers Squibb, Charlotte Jovenin has demonstrated long-term dedication and expertise in her roles. Her extensive experience within the company reflects her deep understanding of the pharmaceutical industry and her capability to adapt to new therapeutic areas, such as her transition from neurosciences to immuno-oncology.